- CME
- Open access
- Published:
Questions and guide to answers
The Egyptian Journal of Internal Medicine volume 26, pages 93–96 (2014)
References
Kulkarni PA, Afehar-Kharghan V. Anticomplement therapy. Biologics 2008; 2: 671–685.
Ricklin D, Ambries JD. Complement-targeted therapeutics. Nat Biotechnol 2007;1265–1275.
Berger SP, Daha MR. Complement in glomerular injury. Semin Immunopathol 2007; 29: 375–384.
Cummings KL, Waggoner SN, Tacke R. Role of complement in immune regulation and its exploitation by virus. Viral Immunol 2007; 20: 505–524.
Griselli M, Herbert J, Hutchinson WL. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999; 190: 1733–1740.
Fu J, Lin G, Wu Z. Anti-apoptotic role for C1 inhibitor in ischemia/ reperfusion-induced myocardial cell injury. Biochem Biophys Res Commun 2006a; 349: 504–512.
Longhi MP, Harris CL, Morgan BP, Gallimore A. Holding T cells in check – a new role for complement regulators? Trends Immunol 2006; 27: 102–108.
Spitzer D, Mitchell LM, Atkinson JP, Hourcade DE. Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J Immunol 2007; 179: 2600–2608.
Guo RF, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol 2005; 23: 821–852.
Wagenaar-Bos IG, Hack CE. Structure and function of C1 -inhibitor. Immunol Allergy Clin North Am 2006; 26: 615–632.
Hill A, Richards SJ, Hillmen P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol 2007; 137: 181–192.
Sim RB, Tsiftsoglou SA. Proteases of the complement system. Biochem Soc Trans 2004; 32: 21–27.
Armstrong PW. et al. Pexelizumab for acute ST-elevation myocardial infarbction in patients undergoing primary percutaneous coronary intervention: A randomized controlled trial. J Am Med Assoc 2007; 297: 43–51.
Monk PN, Scola AM, Madala P, Fairlie DP. Function, structure and therapeutic potential of complement C5a receptors. Br J Pharmacol 2007; 152: 429–448.
Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010; 11: 785–797.
Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C. Terminal complement inhibitor eculizumab in atypical hemolyticuremic syndrome. N Engl J Med 2013; 368: 2169–2181.
Érces, Dániel MD, Nógrády, Miklós, Nagy, Enikő, Varga, Gabriella. Complement C5A antagonist in treatment of cadiogenic shock critical care medicine. 2013; 41.
References
Dent J, Brun J, Fendrick A, et al. An evidence-based appraisal of reflux disease management – the Genval Workshop Report. Gut 1999; 44 (Suppl 2): S1–S16.
Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease – current concepts and dilemmas. Am J Gastroenterol 2001 ; 96: 303–314.
Hershcovici T, Fass R. Nonerosive reflux disease (NERD) – an update. J Neurogastroenterol Motil 2010; 16: 8–21.
Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol 2007; 41: 131–137.
Karamanolis GP, Tutuian R. Role of non-acid reflux in patients with nonerosive reflux disease. Ann Gastroenterol 2013; 26: 100–103.
Fass R. Non-erosive reflux disease (NERD) and erosive esophagitis – a spectrum of disease or special entities? Z Gastroenterol 2007; 45: 1156– 1163.
Sontag SJ, Sonnenberg A, Schnell TG, Leya J, Metz A. The long-term natural history of gastroesophageal reflux disease. J Clin Gastroenterol 2006; 40: 398–404.
Poh CH, Allen L, Malagon I, et al. Risers reflux-an eye-opening experience. Neurogastroentrol Motil 2010; 22: 387–394.
Bytzer P, Blum A, De Herdt D, Dubois D. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2004; 20: 181–188.
Juul-Hansen P, Rydning A. On-demand requirements in patient with endoscopy-negative GERD: H-blocker versus PPI. Aliment Pharmacol Ther 2009; 29: 207–212.
Broeders JAJL, Bredenoord AJ, Hazebroek EJ, Broenders IAMJ, Gooszen HG, Smout AJPM. Effects of antireflux surgery on weakly acidic reflux and belching. Gut 2011 ; 60: 435–441.
Viazis N, Keyoglou A, Kanellopoulos AK, et al. Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: a placebo controlled study using esophageal pH-impedance monitoring. Am J Gastroenterol 2012; 107: 1662–1667.
Iwakiri K, Hayashi Y, Kotoyori M, et al. Defective triggering of secondary peristalsis in patients with non-erosive reflux disease. J Gastroenterol Hepatol 2007; 22: 2208–2211.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Atya, H., Al-Rawi, H. Questions and guide to answers. Egypt J Intern Med 26, 93–96 (2014). https://doi.org/10.4103/1110-7782.139587
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.4103/1110-7782.139587